RareResearch.AI
← Back to atlas

L149V

AlphaMissense: likely benign (0.15)UnknownCytoplasmic · predicted
LeucineValine at position 149 · N-terminal cytoplasmic (intrinsically disordered) · WFS1 (Wolframin)

Interactive 3D Structure

Interactive structure
rotate · zoom · variant + 5 Å neighbors
Fullscreen ↗

Computational Predictions

AlphaMissense
0.152
likely benign
AlphaFold pLDDT
91
model confidence
DynaMut2 ΔΔG
pending
not yet computed
ClinVar
Unknown

AlphaMissense + AlphaFold card. This variant is mapped from AlphaMissense pathogenicity and AlphaFold confidence. The DynaMut2 ΔΔG stability prediction and the wild-type/mutant structural comparison (dual-pane + bond network) are computed per-variant and backfill here — they require a DynaMut2 submission, unlike the precomputed AlphaMissense score.

Clinical Evidence

ClinVar classification
Review status
Associated conditions
Population frequency (gnomAD v4)Ultra-rare · AF 0.000070%
cDNA changec.445T>G
ClinVar accessionVCV004306959
Last evaluated1/01/01 00:00

Observed at very low frequency in gnomAD.

Full Variant Card

L149V — WFS1 Molecular Atlas Card

Variant type: Missense Substitution: Leucine (L) → Valine (V) at position 149 Domain context: N-terminal cytoplasmic (intrinsically disordered)


AlphaMissense

  • Pathogenicity score: 0.1524
  • Class: likely benign

AlphaFold confidence

  • pLDDT at residue 149: 90.56

DynaMut2 ΔΔG: not yet computed for this variant — AlphaMissense + AlphaFold confidence shown above. Stability ΔΔG and the wild-type/mutant structural comparison backfill behind this note.


Clinical evidence

Not found in the cached WFS1 ClinVar set (_reference/WFS1_clinvar_variants.csv).


Card generated by wolfram-atlas-batch (missense AlphaMissense mint) on 2026-06-08T02:27:33.375214Z. AlphaMissense (Cheng et al. 2023) · AlphaFold model v6 · UniProt O76024.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the L149V PDF below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals — guanidinium mimetics, sigma-1 agonist docking, NAC thiol-capping. NAC is already on the bench-testing list.

Download L149V PDF card ↓Strategies are AI-generated predictions, not validated therapeutics.